Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Pedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaPedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie
Zmień bibliotekę

Wyszukujesz frazę "Sebastian, C. Peter" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-10 z 26
Tytuł:
TbRhSn and DyRhSn - Detailed magnetic and ^{119}Sn Mössbauer spectroscopic studies
Autorzy:
Pöttgen, Rainer
Gurgul, Jacek
Peter, Sebastian C.
Łątka, Kazimierz
Pacyna, Andrzej W.
Opis:
The results of magnetic studies and Mössbauer spectroscopic investigations are reported for the stannides TbRhSn and DyRhSn crystallizing in the hexagonal ZrNiAl-type structure. The polycrystalline samples of these ternary intermetallics were synthesized by arc melting from metallic precursors. Detailed ^{119}Sn Mössbauer spectroscopic studies are used to investigate the hyperfine interactions and their temperature evolutions at places occupied by the diamagnetic tin nuclei. Magnetic properties of DyRhSn and TbRhSn were studied by AC/DC magnetometry in a wide temperature range. The results show that both compounds are magnetically ordered at low temperatures. DyRhSn is a non-collinear antiferromagnet with the Néel temperature T_{N} = 7.5 K, whereas TbRhSn undergoes a transition from a paramagnetic to an antiferromagnetic state at T_{N} = 20.2 K. An additional transition at T_{SR} = 10.3 K is detected for TbRhSn which corresponds to some changes in the magnetic moments ordering. The role of the magnetostriction effect in the evolution of the hyperfine parameters and its influence on the observed TbRhSn Mössbauer spectra is discussed. Triangular-like antiferromagnetic arrangements with rare-earth magnetic moments lying in the hexagonal plane are proposed for both compounds at very low temperatures.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
Diabetes mellitus is associated with 90-day mortality in old critically ill COVID-19 patients : a multicenter prospective observational cohort study
Autorzy:
Mayerhöfer, Timo
De Lange, Dylan W.
Wernly, Bernhard
Flaatten, Hans
Moreno, Rui
Guidet, Bertrand
Sigal, Sviri
Bruno, Raphael Romano
Artigas, Antonio
Szczeklik, Wojciech
Leaver, Susannah
Fjolner, Jesper
Cecconi, Maurizio
Joannidis, Michael
Pinto, Bernardo Bollen
Schefold, Joerg C.
Beil, Michael
van Heerden, Peter Vernon
Jung, Christian
Klein, Sebastian
Opis:
Background: Several studies have found an association between diabetes mellitus, disease severity and outcome in COVID-19 patients. Old critically ill patients are particularly at risk. This study aimed to investigate the impact of diabetes mellitus on 90-day mortality in a high-risk cohort of critically ill patients over 70 years of age. Methods: This multicentre international prospective cohort study was performed in 151 ICUs across 26 countries. We included patients ≥ 70 years of age with a confirmed SARS-CoV-2 infection admitted to the intensive care unit from 19th March 2020 through 15th July 2021. Patients were categorized into two groups according to the presence of diabetes mellitus. Primary outcome was 90-day mortality. Kaplan–Meier overall survival curves until day 90 were analysed and compared using the log-rank test. Mixed-effect Weibull regression models were computed to investigate the influence of diabetes mellitus on 90-day mortality. Results: This study included 3420 patients with a median age of 76 years were included. Among these, 37.3% (n = 1277) had a history of diabetes mellitus. Patients with diabetes showed higher rates of frailty (32% vs. 18%) and several comorbidities including chronic heart failure (20% vs. 11%), hypertension (79% vs. 59%) and chronic kidney disease (25% vs. 11%), but not of pulmonary comorbidities (22% vs. 22%). The 90-day mortality was significantly higher in patients with diabetes than those without diabetes (64% vs. 56%, p < 0.001). The association of diabetes and 90-day mortality remained significant (HR 1.18 [1.06–1.31], p = 0.003) after adjustment for age, sex, SOFA-score and other comorbidities in a Weibull regression analysis. Conclusion: Diabetes mellitus was a relevant risk factor for 90-day mortality in old critically ill patients with COVID-19.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Autorzy:
Cheah, Chan Y.
Chavez, Julio C.
Sharman, Jeff P.
Miskin, Hari P.
Hodson, Daniel J.
Leslie, Lori A.
Babu, Sunil
Cheson, Bruce D.
Oconnor, Owen A.
Weiss, Michael S.
Law, Jennie Y.
Samaniego, Felipe
Jurczak, Wojciech
Grosicki, Sebastian
Derenzini, Enrico
Reeves, James A.
Knopinśka-Posłuszny, Wanda
Phillips, Tycel
Lech-Maranda, Ewa
Ghosh, Nilanjan
Burke, John M.
Fonseca, Gustavo
Zinzani, Pier Luigi
Shao, Spencer H.
Pagel, John M.
Fowler, Nathan H.
Caimi, Paolo F.
Sportelli, Peter
Opis:
Purpose: Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein kinase-1ε, exhibits improved selectivity for PI3Kδ compared with other PI3K inhibitors. This phase IIb trial was designed to evaluate the efficacy and safety of umbralisib in patients with R/R iNHL. Patients and Methods; In this multicohort, open-label, phase IIb study, 208 patients with R/R marginal zone, follicular, or small lymphocytic lymphoma (MZL, FL, or SLL) unresponsive to prior treatments (≥ 1 MZL; ≥ 2 FL/SLL), including ≥ 1 anti-CD20–based therapy, were administered umbralisib 800 mg orally once daily until disease progression, unacceptable toxicity, or study withdrawal. Primary end point is overall response rate; secondary end points include time to response, duration of response, progression-free survival, and safety. Results; The median follow-up is 27.7 months (efficacy) and 21.4 months (safety). The overall response rate was 47.1%, and tumor reduction occurred in 86.4% of patients. The median time to response was 2.7-4.6 months. The median duration of response was not reached for MZL, 11.1 months for FL, and 18.3 months for SLL. Median progression-free survival was not reached for MZL, 10.6 months for FL, and 20.9 months for SLL. At least one grade ≥ 3 treatment-emergent adverse event (TEAE) was reported in 53.4% of patients. TEAEs led to umbralisib discontinuation in 32 patients (15.4%). A total of 31 patients (14.9%) discontinued because of a treatment-related adverse event. Grade ≥ 3 TEAEs reported in ≥ 10% of patients: neutropenia (11.5%) and diarrhea (10.1%). Increased ALT/AST (grade ≥ 3) occurred in 6.7%/7.2% of patients. Conclusion; Umbralisib achieved meaningful clinical activity in heavily pretreated patients with iNHL. The safety profile was manageable, with a relatively low incidence of immune-mediated toxicities and adverse event–related discontinuations.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
What makes a theory of consciousness unscientific?
Autorzy:
Seitz, Aaron R.
Rademaker, Rosanne L.
Bengio, Yoshua
Kwok, Sze Chai
Garfinkel, Sarah
Wierzchoń, Michał
Solovey, Guillermo
Charest, Ian
Stein, Timo
Pereplyotchik, David
Schmitz, Michael
Heyes, Cecilia
Frith, Chris D.
Schiller, Daniela
Bisley, James W.
Spiers, Hugo
Kording, Konrad
Carruthers, Peter
Cherkaoui, Mouslim
Odegaard, Brian
Owen, Adrian M.
Carmel, David
Doerig, Adrien
Hassin, Ran R.
Mok, Robert M.
Hsieh, Po-Jang
Ringach, Dario L.
Martinez-Trujillo, Julio
Silvanto, Juha
Bekinschtein, Tristan A.
Or, Charles C.-F.
Shepherd, Joshua
Cheng, Tony
Sebastián, Miguel Ángel
Mobbs, Dean
Carrasco, Marisa
Dennett, Daniel C.
Taschereau-Dumouchel, Vincent
Herzog, Michael H.
Metcalfe, Janet
Tse, Peter U.
Pestilli, Franco
Browning, Jacob
Knapen, Tomas
Frankish, Keith
Slagter, Heleen A.
De Brigard, Felipe
Fleming, Stephen M.
Cumming, Sam
Lieberman, Matthew D.
Schwarzkopf, D. Samuel
Kvamme, Timo L.
Hanson, Jake R.
LeDoux, Joseph
Dijkstra, Nadine
Tong, Frank
Baxter, Mark G.
Buonomano, Dean
Smith, Barry C.
Phillips, Ian
Arnold, Derek H.
Mylopoulos, Myrto
Vibell, Jonas
Cushing, Cody A.
Goodale, Melvyn A.
Miller, Kenneth D.
de Gelder, Beatrice
Kentridge, Robert
Soto, David
Cohen, Michael A.
Carter, Olivia
Corlett, Philip R.
Liu, Ka-Yuet
Watzl, Sebastian
Schurger, Aaron
Weisberg, Josh
Rees, Geraint
Morales, Jorge
Libedinsky, Camilo
Christoff, Kalina
Gottlieb, Jacqueline
Lee, Alan L. F.
Lanfranco, Renzo C.
Webb, Taylor
Konstantinou, Nikos
Machizawa, Maro G.
Klincewicz, Michał
Snyder, Joel S.
Hung, Shao-Min
Scott, Ryan B.
Yan, Karen
Chang, Dorita H. F.
Rahnev, Dobromir
Dux, Paul E.
Roskies, Adina
Wheatley, Thalia
Mitra, Partha P.
Peters, Megan A. K.
Cleeremans, Axel
Lau, Hakwan
Michel, Matthias
Lin, Ying-Tung
Wokke, Martijn E.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Wyświetlanie 1-10 z 26

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies